ATENOLOL Drug Patent Profile

When do Atenolol patents expire, and what generic alternatives are available?

Atenolol is a drug marketed by Able, Aiping Pharm Inc, Apothecon, Aurobindo Pharma, Chartwell Rx, Ipca Labs Ltd, Mylan, Northstar Hlthcare, Nostrum Labs, Novitium Pharma, Pharmobedient, Pliva, SCS, Sun Pharm Inds Inc, Sun Pharm Industries, Teva, Teva Pharms, Unichem, Unique, Watson Labs, Watson Labs Teva, Zydus Pharms Usa, Aurobindo Pharma Usa, and Zydus Pharms. and is included in thirty-nine NDAs.

The generic ingredient in ATENOLOL is atenolol; chlorthalidone. There are thirty-four drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the atenolol; chlorthalidone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Atenolol

A generic version of ATENOLOL was approved as atenolol; chlorthalidone by AIPING PHARM INC on May 31^st, 1990.

Summary for ATENOLOL

US Patents:	0
Applicants:	24
NDAs:	39
Finished Product Suppliers / Packagers:	34
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	124
Patent Applications:	4,041
Drug Prices:	Drug price information for ATENOLOL
Drug Sales Revenues:	Drug sales revenues for ATENOLOL
DailyMed Link:	ATENOLOL at DailyMed

See drug prices for ATENOLOL

See drug sales revenues for ATENOLOL

Recent Clinical Trials for ATENOLOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Department of Cardiology, Gdstrup Hospital, Herning, Denmark	PHASE2
Gdstrup Hospital	PHASE2
VZW Cardiovascular Research Center Aalst	PHASE4

See all ATENOLOL clinical trials

Pharmacology for ATENOLOL

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

Medical Subject Heading (MeSH) Categories for ATENOLOL

Adrenergic beta-1 Receptor Antagonists

Anti-Arrhythmia Agents

Antihypertensive Agents

Sympatholytics

Anatomical Therapeutic Chemical (ATC) Classes for ATENOLOL

C07AB	Beta blocking agents, selective
C07A	BETA BLOCKING AGENTS
C07	BETA BLOCKING AGENTS
C	Cardiovascular system

US Patents and Regulatory Information for ATENOLOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pliva	ATENOLOL AND CHLORTHALIDONE	atenolol; chlorthalidone	TABLET;ORAL	074107-001	Sep 24, 1997		DISCN	No	No
Sun Pharm Inds Inc	ATENOLOL	atenolol	TABLET;ORAL	078210-002	Jul 10, 2007		DISCN	No	No
Pharmobedient	ATENOLOL	atenolol	TABLET;ORAL	073026-002	May 1, 1992	AB	RX	No	No
Teva	ATENOLOL	atenolol	TABLET;ORAL	073316-001	May 28, 1993		DISCN	No	No

Market Dynamics and Financial Trajectory for Atenolol

Last updated: April 19, 2026

What is the current market size for atenolol?

The global atenolol market was valued at approximately $650 million in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 2.5% between 2023 and 2030, reaching nearly $800 million by 2030. This growth reflects sustained demand for beta-blockers in cardiovascular disease management.

What are the primary factors influencing demand?

The main drivers include the high prevalence of hypertension and ischemic heart disease worldwide. According to WHO, over 1.2 billion adults had hypertension in 2019. Atenolol remains a first-line treatment in many developing regions due to its cost-effectiveness. The aging population in North America, Europe, and Asia further increases demand.

How does competitive pressure impact the market?

Market competition primarily comes from other beta-blockers like metoprolol, propranolol, and recently introduced cardioselective agents. Generic versions dominate the market, accounting for roughly 85% of sales, reducing revenue for branded formulations. Patent expirations for atenolol occurred in early 2000s in most jurisdictions, enabling widespread generic entry.

What is the patent status and regulatory landscape?

Atenolol’s patents expired in most countries by 2003. Its regulatory approval has been maintained across key markets. However, recent guidelines emphasize the use of more selective beta-blockers with better side-effect profiles, impacting its prescribing rates.

What are the key market segments?

The market segments include branded prescriptions, generic formulations, and over-the-counter (OTC) sales in some regions. Geographically, North America accounts for approximately 35% of sales, Europe 25%, and Asia-Pacific 30%, with the remaining 10% in Latin America and Africa.

What are the trends shaping the future?

Judicial shifts toward personalized medicine lead to decreased use of atenolol in some countries due to evidence favoring drugs with fewer adverse effects. The rise of combination therapies with other antihypertensives presents opportunities but also cannibalizes monotherapy sales. The expansion of telemedicine and electronic prescribing influences procurement patterns.

What are the regulatory and policy influences?

Regulatory agencies like the FDA and EMA have issued guidelines emphasizing safety profiles, which favor cardioselective beta-blockers. Some countries have updated hypertension treatment guidelines, recommending alternatives to atenolol for initial therapy.

Financial trajectory analysis

Year	Market Size (USD million)	CAGR	Notes
2022	650	—	Base year
2023	666	2.5%	Projected
2025	705	2.5%	Mid-term target
2030	800	2.5%	Long-term projection

The revenue is expected to experience incremental growth mainly stemming from market expansion in emerging markets and increased demand for generic drugs. However, revenue from branded formulations will decline as patent protections have waned.

What are the key challenges?

• Declining prescribing rates due to newer beta-blockers with better safety profiles.
• Regulatory shifts favoring targeted therapies over broad-spectrum drugs like atenolol.
• Market saturation in established regions.
• Price pressures from generic competition.

What opportunities exist?

• Developing combination therapies integrating atenolol with other antihypertensives.
• Exploring new indications, such as migraine prophylaxis or certain arrhythmias.
• Expanding market share in emerging regions with rising hypertension prevalence.
• Repositioning strategies to differentiate formulations or delivery methods.

Conclusion

Atenolol market dynamics show steady but slowing growth driven by demographic trends and generic competition. Future revenue streams depend on strategic positioning in emerging markets and formulation innovations.

Key Takeaways

• The global atenolol market was valued at $650 million in 2022.
• Demand driven by hypertension and ischemic heart disease prevalence.
• Patent expirations have led to widespread generics, compressing margins.
• Market growth projected at 2.5% CAGR through 2030, reaching $800 million.
• Regulatory and clinical guideline shifts favor cardioselective beta-blockers, impacting atenolol prescribing.

FAQs

1. What are the main competitors to atenolol?
   Metoprolol, propranolol, and bisoprolol.

2. Are there any new formulations or delivery methods?
   No significant innovations in atenolol delivery; focus remains on generics.

3. Is atenolol used for indications beyond hypertension?
   Yes; it is used for angina, arrhythmias, and migraine prevention, though less commonly today.

4. How do price pressures affect market profitability?
   High generic competition leads to significant price reductions, squeezing profit margins.

5. What regions are expected to see the fastest growth?
   Emerging markets in Asia-Pacific and Latin America, driven by rising hypertension prevalence and healthcare infrastructure improvements.

References

1. World Health Organization. (2019). Hypertension prevalence estimates. World Health Organization.
2. Statista. (2023). Global beta-blocker market report.
3. U.S. Food and Drug Administration. (2022). Drug approvals and guidelines.
4. European Medicines Agency. (2022). Pharmacovigilance and regulatory updates.
5. MarketResearch.com. (2023). Cardiovascular drugs: market trends and forecasts.